PDF Download

Subscrition price for capital increase against cash contribution fixed at € 33.50

25.09.2015

With consent of the Supervisory Board, the Management Board of Deutsche Biotech Innovativ AG (“DBI“) fixed the subscription price for the planned capital increase at € 33.50 per share.

In the context of a capital increase against cash contribution, which had been resolved by the annual general meeting of DBI AG in July, up to 596,400 new shares shall be issued. By this, DBI aims at raising gross proceeds of around € 20 million.

The new shares shall be offered to the existing shareholders via preemptive rights for the named subscription price of € 33.50 per share and for a period of at least two weeks. Any shares not subscribed after the end of the subscription period will be offered to the shareholders and interested investors for subscription. The capital increase shall be conducted until November 2015 at the latest based on a securities prospectus, which is still to be published.


About Deutsche Biotech Innovativ AG
Deutsche Biotech Innovativ AG (“DBI”) is a biotechnology company that uses innovative blood biomarkers to research and clinically develop unique therapeutic solutions for serious illnesses for which no adequate medical solutions have yet been found. Its focus is on drugs for sepsis and cancer. The company's main product is the patented drug Adrecizumab for decreasing mortality due to organ failure in septic shock. Adrecizumab has successfully completed the preclinical phase and will be tested in a Phase I study starting in 2015.

The preclinical and clinical studies are mainly carried out by project companies in which DBI AG holds a stake. Currently, DBI AG holds 26% of AdrenoMed AG (Agent: Adrecizumab), 25% of Oncoprevent GmbH (Agent: DB1RA), 100% of AngioBiomed GmbH (Agent: AB2302) and 50% of My Life Diagnostics GmbH (Diagnostic agent for urinary tract infection).

DBI aims to further expand its drug pipeline and invest in the research and development of drugs that have high unique-selling-point potential.

Both members of DBI's Management Board, Dr. Bernd Wegener and Dr. Andreas Bergmann, have many years of experience in the biotechnology field. Both were founders and part of the management team of B.R.A.H.M.S. AG, a highly successful biotechnology company specialising in the identification of blood biomarkers for treating serious illnesses. It was sold in 2009 for around € 330 million. Dr. Bernd Wegener is also a member of the Executive Board of the Association of the German Pharmaceutical Industry (Bundesverband der Pharmazeutischen Industrie).

For more information, please contact:

Deutsche Biotech Innovativ AG
Ms. Susanne Wallace
Tel.: +49 (0)3302 20 77 811
E-Mail: s.wallace@dbi-ag.de

Kirchhoff Consult AG
Ms. Anja Ben Lekahl
Tel.: +49 (0)40 609 186 55
E-mail: anja.benlekhal@kirchhoff.de

published:  

http://www.dgap.de/dgap/News/corporate/deutsche-biotech-innovativ-subscrition-price-for-capital-increase-against-cash-contribution-fixed-eur/?companyID=363635&newsID=900291